Dmitry Balyasny’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.18M | Buy |
5,100
+3,400
| +200% | +$2.31M | ﹤0.01% | 1596 |
|
|
2026
Q1 | $1.31M | Sell |
1,700
-10,300
| -86% | -$7.89M | ﹤0.01% | 1963 |
|
|
2025
Q4 | $9.26M | Buy |
12,000
+4,600
| +62% | +$3.12M | 0.01% | 1063 |
|
|
2025
Q3 | $4.16M | Sell |
7,400
-7,400
| -50% | -$4.18M | 0.01% | 1447 |
|
|
2025
Q2 | $7.77M | Buy |
+14,800
| New | +$8.26M | 0.01% | 1083 |
|
|
2025
Q1 | – | Sell |
-1,400
| Closed | -$997K | – | 3205 |
|
|
2024
Q4 | $997K | Sell |
1,400
-2,800
| -67% | -$2.35M | ﹤0.01% | 1951 |
|
|
2024
Q3 | $4.42M | Buy |
4,200
+1,900
| +83% | +$2.11M | 0.01% | 1312 |
|
|
2024
Q2 | $2.42M | Buy |
2,300
+1,700
| +283% | +$1.65M | ﹤0.01% | 1462 |
|
|
2024
Q1 | $577K | Buy |
+600
| New | +$571K | ﹤0.01% | 1998 |
|
|
2023
Q4 | – | Sell |
-5,600
| Closed | -$4.61M | – | 2829 |
|
|
2023
Q3 | $4.61M | Hold |
5,600
| – | – | 0.01% | 1130 |
|
|
2023
Q2 | $4.02M | Hold |
5,600
| – | – | 0.01% | 1139 |
|
|
2023
Q1 | $4.6M | Hold |
5,600
| – | – | 0.01% | 1117 |
|
|
2022
Q4 | $4.04M | Sell |
5,600
-100
| -2% | -$73.8K | 0.01% | 1121 |
|
|
2022
Q3 | $3.93M | Buy |
5,700
+4,300
| +307% | +$2.71M | 0.01% | 1138 |
|
|
2022
Q2 | $828K | Buy |
+1,400
| New | +$910K | ﹤0.01% | 1825 |
|
|
2021
Q3 | – | Sell |
-27,400
| Closed | -$15.3M | – | 2342 |
|
|
2021
Q2 | $15.3M | Buy |
+27,400
| New | +$13.9M | 0.07% | 370 |
|
|
2020
Q4 | – | Sell |
-100,000
| Closed | -$56M | – | 1631 |
|
|
2020
Q3 | $56M | Buy |
+100,000
| New | +$60.6M | 0.41% | 39 |
|
|
2019
Q4 | – | Sell |
-135,000
| Closed | -$37.4M | – | 1441 |
|
|
2019
Q3 | $37.4M | Buy |
135,000
+35,000
| +35% | +$10.4M | 0.26% | 103 |
|
|
2019
Q2 | $32M | Buy |
100,000
+63,000
| +170% | +$21M | 0.2% | 136 |
|
|
2019
Q1 | $15.2M | Buy |
+37,000
| New | +$15.2M | 0.1% | 287 |
|
|
2018
Q4 | – | Sell |
-105,500
| Closed | -$40.5M | – | 1694 |
|
|
2018
Q3 | $40.5M | Buy |
105,500
+39,000
| +59% | +$14.8M | 0.18% | 146 |
|
|
2018
Q2 | $22.9M | Sell |
66,500
-42,500
| -39% | -$13.3M | 0.1% | 278 |
|
|
2018
Q1 | $37.5M | Sell |
109,000
-38,500
| -26% | -$13.4M | 0.16% | 184 |
|
|
2017
Q4 | $55.5M | Buy |
+147,500
| New | +$59.7M | 0.17% | 149 |
|
|
2017
Q3 | – | Sell |
-365,000
| Closed | -$179M | – | 2061 |
|
|
2017
Q2 | $179M | Buy |
+365,000
| New | +$160M | 0.74% | 12 |
|
Other funds holding REGN
Dmitry Balyasny's REGN Position: Q2 2026 in Review
Dmitry Balyasny increased its Regeneron Pharmaceuticals (REGN) stake by 527% in Q2 2026, buying an estimated $5.4M and bringing the position to 9,432 shares worth $5.88M. The position accounts for 0.01% of the portfolio, ranked #1307.
Dmitry Balyasny first reported a position in REGN in Q2 2013 and has held it in 28 quarters since. The position peaked at $81.1M in Q2 2019. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Dmitry Balyasny held 9,432 shares of Regeneron Pharmaceuticals worth $5.88M as of Q2 2026.
- Dmitry Balyasny bought 7,927 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.4M.
- Regeneron Pharmaceuticals made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1307 holding.
- Dmitry Balyasny first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 28 quarters since.
- Dmitry Balyasny's Regeneron Pharmaceuticals position peaked at $81.1M in Q2 2019.
- 1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.